Abstract:Background: Breast cancer, despite significant advancements in treatment, remains a major cause of cancer-related deaths among women. Immunotherapy, an emerging therapeutic strategy, offers promise for better outcomes, particularly through the modulation of immune functions. Glioma-Associated Oncogene Homolog 1 (GLI1), a transcription factor implicated in cancer biology, has shown varying roles in different cancers. However, its immunoregulatory functions in breast invasive carcinoma (BRCA) remain elusive. The current study aimed to unravel the expression patterns and immune-regulatory roles of GLI1 in BRCA. Methods: Utilizing multiple bioinformatic platforms (TIMER2.0, GEPIA2, and R packages) based on The Cancer Genome Atlas (TCGA) and/or Genotype-Tissue Expression (GTEx) databases, we analyzed the expression of GLI1 in BRCA and its pan-cancer expression profiles. We further validated these findings by conducting qPCR and immunohistochemical staining on clinical BRCA samples. Kaplan-Meier analysis and Cox proportional hazards regression were performed to assess the prognostic value of GLI1. Additionally, the association between GLI1 expression and immune infiltration within the tumor immune microenvironment (TMIE) was examined. Results: The findings reveal dysregulated expression of GLI1 in numerous cancers, with a significant decrease observed in BRCA. High GLI1 expression indicated better survival outcomes and was correlated with the age and stage of BRCA patients. GLI1 was involved in immune status, as evidenced by its strong correlations with immune and stromal scores and the infiltration levels of multiple immune cells. Meanwhile, GLI1 was co-expressed with multiple immune-related genes, and high GLI1 expression was associated with the activation of immune-related pathways, such as binding to proteasome and mismatch repair and retinol metabolism signaling pathways. Additionally, the differential expression of GLI1 may be related to the effect of immunotherapy on CTLA-4, PD-1, and other signals, and can effectively predict the immune efficacy. Conclusion: Our study underscores the critical role of GLI1 in BRCA, both as a potential tumor suppressor and an immune regulator. The association between GLI1 expression and favorable prognosis suggests its potential as a prognostic biomarker and immunotherapeutic target in BRCA.

The roles of BTG1 mRNA expression in cancers: A bioinformatics analysis

Btg1 Expression Correlates With The Pathogenesis And Progression Of Ovarian Carcinomas

BTG1 Overexpression Might Promote Invasion and Metastasis of Colorectal Cancer via Decreasing Adhesion and Inducing Epithelial–Mesenchymal Transition

The expression of BTG1 is downregulated in NSCLC and possibly associated with tumor metastasis

Btg1 Inhibits Breast Cancer Cell Growth Through Induction Of Cell Cycle Arrest And Apoptosis

B‑cell translocation 1 gene inhibits cellular metastasis‑associated behavior in breast cancer.

The effect of BTG1 expression on proliferation, apoptosis and invasion of non-small cell lung cancer cells

Upregulated TUBG1 expression is correlated with poor prognosis in hepatocellular carcinoma

Expression and Prognosis Analyses of the Tob/BTG Antiproliferative (APRO) Protein Family in Human Cancers

ITGB1 As a Prognostic Biomarker Correlated with Immune Suppression in Gastric Cancer

Expression and Prognostic Value of APRO Family in Gastric Cancer

TuBG1 promotes hepatocellular carcinoma via ATR/P53-apoptosis and cycling pathways

Glioma-associated oncogene homolog 1 in breast invasive carcinoma: a comprehensive bioinformatic analysis and experimental validation

BTG2 Is Down-Regulated and Inhibits Cancer Stem Cell-Like Features of Side Population Cells in Hepatocellular Carcinoma

Identification of functional genes regulating gastric cancer progression using integrated bioinformatics analysis

A multi-cancer analysis unveils ITGBL1 as a cancer prognostic molecule and a novel immunotherapy target

Upregulation of BTG1 Enhances the Radiation Sensitivity of Human Breast Cancer in Vitro and in Vivo

Research Progress of BTG2 As a Tumor Prognostic Factor

P3.16-01 A Multi-Omic Study Reveals BTG2 As a Reliable Prognostic Marker for Early-Stage Non-Small Cell Lung Cancer

Expression of BTG1 in HK-2 and 786-O and Its Influence on Cell Cycle and Apoptosis of HK-2 and 786-O

BTG2 As a Tumor Target for the Treatment of Luminal A Breast Cancer